Cofttek holdings limited

Wnt&Beta catenin

SU-5607 (186611-52-9)

SU5607 (IC261), purity > 98%, is in stock. The same day shipping out after order is received.

Not Intended for Therapeutic Use. For research use only.

CAS: 186611-52-9 Category

SU-5607 (186611-52-9) Description

SU5607, also known as IC-261, is a potent and selective CK1 inhibitor. IC261 triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. At low micromolar concentrations IC261 inhibits cytokinesis causing a transient mitotic arrest. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing.


SU-5607 (186611-52-9) Specifications

Product Name SU-5607
Synonym  IC261; IC-261; IC 261 SU5607; SU-5607; SU 5607.
Chemical Name (E)-3-(2,4,6-trimethoxybenzylidene)indolin-2-one
Drug Class N/A
Purity ≥ >98%
CAS Number  186611-52-9
Molecular Formula C19H22Cl2FN5
Molecular Weight 311.34
Monoisotopic Mass 311.11576
MDL number SML0795
InChi Code InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+
Form  PF670462
Color yellow
Solubility  Soluble in DMSO
Storage Temp.  0 – 4 C for short term (days to weeks), or -20 C for long term (months).
Shelf life > >2 years if stored properly
Handling N/A
Application N/A



RIDADR NONH for all modes of transport


[1]. Keenan CR, Langenbach SY, Jativa F, Harris T, Li M, Chen Q, Xia Y, Gao B, Schuliga MJ, Jaffar J, Prodanovic D, Tu Y, Berhan A, Lee PVS, Westall GP, Stewart AG. Front Pharmacol. 2018 Jul 10;9:738. doi: 10.3389/fphar.2018.00738. eCollection 2018.

[2]. Hiramoto K, Yamate Y, Kasahara E, Sato EF. Int J Biol Sci. 2018 Jun 2;14(9):992-999. doi: 10.7150/ijbs.24558. eCollection 2018.

[3]. Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, Skabrahova H, Radaszkiewicz T, Ovesna P, Vondalova Blanarova O, Nemcova T, Hoferova Z, Vasickova K, Smyckova L, Egle A, Pavlova S, Poppova L, Plevova K, Pospisilova S, Bryja V. Blood. 2018 Mar 15;131(11):1206-1218. doi: 10.1182/blood-2017-05-786947. Epub 2018 Jan 9.

[4].Wager TT, Galatsis P, Chandrasekaran RY, Butler TW, Li J, Zhang L, Mente S, Subramanyam C, Liu S, Doran AC, Chang C, Fisher K, Grimwood S, Hedde JR, Marconi M, Schildknegt K. ACS Chem Neurosci. 2017 Sep 20;8(9):1995-2004. doi: 10.1021/acschemneuro.7b00155. Epub 2017 Jun 30.

[5]. Patton AP, Chesham JE, Hastings MH. J Neurosci. 2016 Sep 7;36(36):9326-41. doi: 10.1523/JNEUROSCI.0958-16.2016.